Metabolic Communication by SGLT2 Inhibition
Circulation · 12.03.2024 · 149 (11) · 860-884
DOI: 10.1161/circulationaha.123.065517 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 12.03.2024. Verfasst von Anja M Billing und 34 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Biomedicine (A.M.B., F.D., E.K., J.J., R.A.F., M.C., M.M.R.), Aarhus University, Denmark. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Experimental, Induced Pluripotent Stem Cells, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 163-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NIGMS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect the kidneys and heart, but the underlying mechanism remains poorly understood. METHODS: To gain insights on primary effects of SGLT2i that are not confounded by pathophysiologic processes or are secondary to improvement by SGLT2i, we performed an in-depth proteomics, phosphoproteomics, and metabolomics analysis by integrating signatures from multiple metabolic organs and body fluids after 1 week of SGLT2i treatment of nondiabetic as well as diabetic mice with early and uncomplicated hyperglycemia. RESULTS: Kidneys of nondiabetic mice reacted most strongly to SGLT2i in terms of proteomic reconfiguration, including evidence for less early proximal tubule glucotoxicity and a broad downregulation of the apical uptake transport machinery (including sodium, glucose, urate, purine bases, and amino acids), supported by mouse and human SGLT2 interactome studies. SGLT2i affected heart and liver signaling, but more reactive organs included the white adipose tissue, showing more lipolysis, and, particularly, the gut microbiome, with a lower relative abundance of bacteria taxa capable of fermenting phenylalanine and tryptophan to cardiovascular uremic toxins, resulting in lower plasma levels of these compounds (including p-cresol sulfate). SGLT2i was detectable in murine stool samples and its addition to human stool microbiota fermentation recapitulated some murine microbiome findings, suggesting direct inhibition of fermentation of aromatic amino acids and tryptophan. In mice lacking SGLT2 and in patients with decompensated heart failure or diabetes, the SGLT2i likewise reduced circulating p-cresol sulfate, and p-cresol impaired contractility and rhythm in human induced pluripotent stem cell–derived engineered heart tissue. CONCLUSIONS: SGLT2i reduced microbiome formation of uremic toxins such as p-cresol sulfate and thereby their body exposure and need for renal detoxification, which, combined with direct kidney effects of SGLT2i, including less proximal tubule glucotoxicity and a broad downregulation of apical transporters (including sodium, amino acid, and urate uptake), provides a metabolic foundation for kidney and cardiovascular protection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Biomedicine (A.M.B., F.D., E.K., J.J., R.A.F., M.C., M.M.R.), Aarhus University, Denmark.
- Departments of Medicine and Pharmacology, University of California San Diego, La Jolla (Y.C.K., M.C.-M., V.V.).
- VA San Diego Healthcare System, CA (Y.C.K., M.C.-M., V.V.).
- Clinical Medicine (S.G., P.L.P.), Aarhus University, Denmark.
- Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark (S.G., E.L.).
- Department of Cardiology, University Heart and Vascular Center Hamburg, Germany (B.S., S.B., P.K., T.Z., C.M.).
ORCID-Profile: Anja M Billing, Søren Gullaksen, Benedikt Schrage, Arvid Hutzfeldt, Fatih Demir, Moritz Lassé, Robin Fallegger, Qing Li, Olha Kravtsova, Amelia Palermo, Stefan Blankenberg, Paulus Kirchhof, Tobias B Huber, Esben Laugesen, Maria Chrysopoulou, Julio Saez-Rodriguez, Christina Magnussen, Thomas Eschenhagen, Alexander Staruschenko, Gary Siuzdak, Clarissa Schwab, Friederike Cuello, Volker Vallon, Markus M Rinschen
Förderung
- NIDDK NIH HHS
- NIGMS NIH HHS
- NHLBI NIH HHS
- NIA NIH HHS
Zitieren
APA
Billing, A. M., Kim, Y. C., Gullaksen, S., Schrage, B., Raabe, J., Hutzfeldt, A., Demir, F., Kovalenko, E., Lassé, M., Dugourd, A., Fallegger, R., Klampe, B., Jaegers, J., Li, Q., Kravtsova, O., Crespo-Masip, M., Palermo, A., Fenton, R. A., Hoxha, E., …, & Rinschen, M. M. (2024). Metabolic Communication by SGLT2 Inhibition. Circulation, 149(11), 860-884. https://doi.org/10.1161/circulationaha.123.065517
Vancouver
Billing AM, Kim YC, Gullaksen S, Schrage B, Raabe J, Hutzfeldt A, et al. Metabolic Communication by SGLT2 Inhibition. Circulation. 2024;149(11):860-884. doi:10.1161/circulationaha.123.065517
BibTeX
@article{Billing2024,
author = {Billing, Anja M and Kim, Young Chul and Gullaksen, Søren and Schrage, Benedikt and Raabe, Janice and Hutzfeldt, Arvid and Demir, Fatih and Kovalenko, Elina and Lassé, Moritz and Dugourd, Aurelien and Fallegger, Robin and Klampe, Birgit and Jaegers, Johannes and Li, Qing and Kravtsova, Olha and Crespo-Masip, Maria and Palermo, Amelia and Fenton, Robert A and Hoxha, Elion and Blankenberg, Stefan and Kirchhof, Paulus and Huber, Tobias B and Laugesen, Esben and Zeller, Tanja and Chrysopoulou, Maria and Saez-Rodriguez, Julio and Magnussen, Christina and Eschenhagen, Thomas and Staruschenko, Alexander and Siuzdak, Gary and Poulsen, Per L and Schwab, Clarissa and Cuello, Friederike and Vallon, Volker and Rinschen, Markus M},
title = {Metabolic Communication by SGLT2 Inhibition},
journal = {Circulation},
year = {2024},
volume = {149},
number = {11},
pages = {860--884},
doi = {10.1161/circulationaha.123.065517}
}
EUVIMED